Cell therapy involves transplanting damaged cells/tissue with healthy human cells. Since, the nineteenth century, concept of cell therapy was established. However, its complete potential is being released now. At present, T-cells (cancer fighting cells) are extensively used against cancer, i.e., in immunotherapy. Potential for treating diseases like Parkinson's disease, schizophrenia, Alzheimer's disease, etc. and reduced therapeutics related risks are some of the major advantages associated with cell therapy.
In recent years, the cell therapy market has witnessed rapid growth owing to favorable reimbursement process, strong clinical pipeline, increasing global burden of diseases (cancer, cardiovascular diseases, diabetes, etc.), and increasing FDA approvals. It is reported that the prevalence of cancer is increasing, thus, the demand of effective based therapeutics, i.e., “cell therapy”. As per the fact sheet published by the American Cancer Society in 2016, ~1,685,210 new cases of cancer were reported within the US. Thus, increasing prevalence of cancer is estimated to be major driver for the market growth. Moreover, rising governments R&D and favorable reimbursement policies, w.r.t. cell therapy based. According boosts the market growth. According to an article published by the STEM CELLS Translational Medicine in 2017, it was reported that products like HeartSheet by Terumo comes with a reimbursement price of ~ USD 120,000. Such trends in the market is estimated to increase the patient population seeking cell-therapy based therapeutics. However, stringent FDA approvals, changing regulatory framework and high cost of cell therapy & related products restraints the market growth during the forecast period. The cost for a cell therapy session is estimated to be about USD 8000-10,000.
Segmentation
The global cell therapy market is segmented into type, source, application, end user, and region. Based on type, the global cell therapy market is segmented into allogenic cell therapy and autologous cell therapy.
On the basis of source, the market is segmented into bone marrow, embryo/spinal cord, peripheral blood, adipose, spine, and others.
The application segment is divided into oncology, autoimmune, dermatology, cardiovascular, neurology, and musculoskeletal diseases. The neurology segmented is further divided into mesenchymal stem cells, human neural stem cells, bone marrow mononuclear cell, and others. The oncology segment is sub-segmented into human pluripotent stem cells, peripheral blood stem cells, mesenchymal stem cells, and others. The autoimmune segment is sub-segmented into mesenchymal stem cells, adipose derived stem cells, peripheral blood stem cells mesenchymal stem cells, human pluripotent stem cells, and others. The dermatology segment is sub-divided into mesenchymal stem cells, adipose derived stem cells, and others. The cardiovascular segment is sub-segmented into mesenchymal stem cells, adipose derived stem cells, bone marrow mononuclear cell, cd 34+, and others. The Musculoskeletal segment is sub-segmented into bone marrow mononuclear cell, mesenchymal stem cells, adipose derived stem cells, and others.
On the basis of end user, the global cell therapy market is segmented into hospitals & medical research institutes, biotechnology & contract research organizations, and stem cell banks.
Regional
The Americas led the market in 2018 owing to high per capita healthcare expenditure, rising prevalence of diseases, presence of major market players, and a well-established healthcare infrastructure within the region. Following similar trends, Europe stood second in the global cell therapy market. Government support, presence of developed economies, and rising R&D expenditure drives the European market. Asia Pacific is the growing region in the global cell therapy market. This can be attributed to the growing healthcare sector, increasing R&D, and rising contract research organizations (CROs) provide within the region. On the other hand, the Middle East & Africa is estimated to hold the least market share.
Key Players
Many local and global players are operating in the market. They are focusing on product development & improvement, geographical expansion and acquisitions. The competition in the market is increasing and companies are seeing Asia Pacific region as new revenue pockets. Some of the key players in the market are inclusive of Anterogen Co., Ltd., Astellas Pharma Inc., BioTime Inc., BrainStorm Cell Therapeutics Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., Cytori Therapeutics, Inc., MEDIPOST Co., Ltd., NUVASIVE, INC, Osiris Therapeutics, Inc., Pharmicell Co., Ltd., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific, U.S. Stem Cell, Inc, Terumo, and others.
